GLPwatch
Papers (10373)
Page 38 of 173, ranked by citation count.
- Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH.
- 68Ga-NOTA-exendin-4 PET/CT in detection of occult insulinoma and evaluation of physiological uptake.
- Recent guidelines for Non-Alcoholic Fatty Liver disease (NAFLD)/ Fatty Liver Disease (FLD): Are they already outdated and in need of supplementation?
- The kidney and cardiovascular outcome trials.
- Exenatide (a GLP-1 agonist) improves the antioxidative potential of in vitro cultured human monocytes/macrophages.
- Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
- Rgs16 and Rgs8 in embryonic endocrine pancreas and mouse models of diabetes.
- Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies.
- Current Drug Targets in Obesity Pharmacotherapy - A Review.
- Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT.
- Oral Semaglutide Induces Loss of Body Fat Mass Without Affecting Muscle Mass in Patients With Type 2 Diabetes.
- Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial.
- Exenatide can inhibit calcification of human VSMCs through the NF-kappaB/RANKL signaling pathway.
- Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis.
- Clinical Outcomes by Albuminuria Status with Dulaglutide versus Insulin Glargine in Participants with Diabetes and CKD: AWARD-7 Exploratory Analysis.
- Dulaglutide exerts beneficial anti atherosclerotic effects in ApoE knockout mice with diabetes: the earlier, the better.
- Mitigation of autophagy ameliorates hepatocellular damage following ischemia-reperfusion injury in murine steatotic liver.
- SGLT2 inhibitors and incretin agents: Associations with alanine aminotransferase activity in type 2 diabetes.
- Obesity and GLP-1.
- Incretin-Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes.
- Glucagon-like peptide agonists for weight management in antipsychotic-induced weight gain: A systematic review and meta-analysis.
- Weight loss efficiency and safety of tirzepatide: A Systematic review.
- Glucagon-like peptide-1 receptor agonist-based agents and weight loss composition: Filling the gaps.
- Semaglutide and the risk of diabetic retinopathy-current perspective.
- Exendin-4 Induces Bone Marrow Stromal Cells Migration Through Bone Marrow-Derived Macrophages Polarization via PKA-STAT3 Signaling Pathway.
- Evidence that tirzepatide protects against diabetes-related cardiac damages.
- Real-World Use of Semaglutide for Weight Management: Patient Characteristics and Dose Titration-A Danish Cohort Study.
- Anti-IL-21 monoclonal antibody combined with liraglutide effectively reverses established hyperglycemia in mouse models of type 1 diabetes.
- Does receptor balance matter? - Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models.
- Efficacy of liraglutide 3.0 mg treatment on weight loss in patients with weight regain after bariatric surgery.
- High-fat diet changes the temporal profile of GLP-1 receptor-mediated hypophagia in rats.
- Synergistic anti-tumor effects of Liraglutide, a glucagon-like peptide-1 receptor agonist, along with Docetaxel on LNCaP prostate cancer cell line.
- GLP-1 receptor agonist impairs keratinocytes inflammatory signals by activating AMPK.
- Semaglutide alters gut microbiota and improves NAFLD in db/db mice.
- Dissolving microneedle-assisted long-acting Liraglutide delivery to control type 2 diabetes and obesity.
- Liraglutide alleviates diabetic cardiomyopathy by blocking CHOP-triggered apoptosis via the inhibition of the IRE-α pathway.
- Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry.
- GLP-1 receptor agonist attenuates tubular cell ferroptosis in diabetes via enhancing AMPK-fatty acid metabolism pathway through macropinocytosis.
- Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide.
- Estimands, Estimators, and Estimates.
- Fluorescent exendin-4 derivatives for pancreatic β-cell analysis.
- Semaglutide ameliorates obesity-induced cardiac inflammation and oxidative stress mediated via reduction of neutrophil Cxcl2, S100a8, and S100a9 expression.
- Narrative Review of Effects of Glucagon-Like Peptide-1 Receptor Agonists on Bone Health in People Living with Obesity.
- Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial.
- Liraglutide Regulates Mitochondrial Quality Control System Through PGC-1α in a Mouse Model of Parkinson's Disease.
- Exenatide treatment exerts anxiolytic- and antidepressant-like effects and reverses neuropathy in a mouse model of type-2 diabetes.
- Exendin-4 inhibits iNOS expression at the protein level in LPS-stimulated Raw264.7 macrophage by the activation of cAMP/PKA pathway.
- Effects of glucagon-like peptide-1 receptor agonists on mortality and cardiovascular events: A comprehensive meta-analysis of randomized controlled trials.
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- Role of liraglutide in brain repair promotion through Sirt1-mediated mitochondrial improvement in stroke.
- Predictors of weight-loss response with glucagon-like peptide-1 receptor agonist treatment among adolescents with severe obesity.
- Exendin-4 inhibits glucolipotoxic ER stress in pancreatic β cells via regulation of SREBP1c and C/EBPβ transcription factors.
- Dulaglutide mitigates inflammatory response in fibroblast-like synoviocytes.
- Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus.
- Effect of semaglutide 2.4 mg on physical functioning and weight- and health-related quality of life in adults with overweight or obesity: Patient-reported outcomes from the STEP 1-4 trials.
- Glucagon-like peptide receptor agonists attenuate advanced glycation end products-induced inflammation in rat mesangial cells.
- Clinical effectiveness of semaglutide on weight loss, body composition, and muscle strength in Chinese adults.
- Pancreatic insulin and exocrine secretion are under the modulatory control of distinct subpopulations of vagal motoneurones in the rat.
- Liraglutide suppresses obesity and induces brown fat-like phenotype via Soluble Guanylyl Cyclase mediated pathway in vivo and in vitro.
- Oral delivery of exenatide-loaded hybrid zein nanoparticles for stable blood glucose control and β-cell repair of type 2 diabetes mice.